Saint-Petersburg, Russia, February 13, 2014 --(PR.com
)-- At the end of 2013, BIOCAD also signed a definitive agreement with AMPHI PTE Ltd., a known Singapore pharmaceuticals company. According to the terms of the agreement, BIOCAD’s partner in Singapore will be granted the exclusive right to distribute Zolerix® in two countries: Cambodia and Singapore. Zolerix® prevents the patients with breast cancer, prostate cancer and other solid tumors with metastatic lesions to bones from the development of pathologic fracture, compression of spinal cord, decreases the necessity of X-ray therapy and surgical measures and reduces tumor hypercalcemia.
According to Dr. Roman Ivanov, BIOCAD’s Vice-President for Research and Development, “These agreements have become the logical result of the persistent, continuous work to expand the geography of BIOCAD’s medications, which are undoubtedly in demand in many international markets due to the extremely attractive ratio of reasonable price to their high quality.”